The U.S Food and Drug Administration granted tentative approval to Mylan NV's generic HIV treatment under the U.S. President's Emergency Plan for AIDS Relief.
The anti-retroviral treatment, known as TDF-3TC-DTG, or TLD, is recommended as the first line of treatment for patients in developing countries. The drug combines the active ingredients from three brand-name medicines: ViiV Healthcare's Tivicay and Epivir, and Gilead Sciences Inc.'s Viread.
The U.S. President's Emergency Plan for AIDS Relief is a U.S. government initiative to address the global HIV/AIDS epidemic, primarily in Africa.
ViiV Healthcare is majority owned by GlaxoSmithKline plc